Literature DB >> 14583875

Linezolid-associated toxic optic neuropathy: a report of 2 cases.

Elsie Lee1, Susanne Burger, Jilan Shah, Christine Melton, Michael Mullen, Floyd Warren, Robert Press.   

Abstract

We describe 2 cases in which the prolonged use of linezolid to treat complicated methicillin-resistant Staphylococcus aureus infections was followed by acutely developed blurred vision and progressive loss of vision and color perception during the ensuing few weeks. Both patients received a diagnosis of toxic optic neuropathy, and linezolid therapy was stopped. The patients experienced an initial rapid partial improvement and a subsequent gradual, almost complete, recovery over many months.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583875     DOI: 10.1086/379012

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Linezolid induced toxic optic neuropathy.

Authors:  K Kulkarni; L V Del Priore
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

Review 2.  Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

3.  Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients.

Authors:  Emma Bishop; Sharmila Melvani; Benjamin P Howden; Patrick G P Charles; M Lindsay Grayson
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.

Authors:  E E McKee; M Ferguson; A T Bentley; T A Marks
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 5.  Linezolid-induced optic neuropathy: a mitochondrial disorder?

Authors:  M Javaheri; R N Khurana; T M O'hearn; M M Lai; A A Sadun
Journal:  Br J Ophthalmol       Date:  2007-01       Impact factor: 4.638

6.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

7.  Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Authors:  A Louie; H S Heine; K Kim; D L Brown; B VanScoy; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

Review 8.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

10.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.